65,437 trials
Oxidative Stress · Inflammation · Blood Pressure
Primary: Biomarkers of Antioxidant Activity-Total Antioxidant Capacity (TAC) and Superoxide Dismutase (SOD) — 6.09; 5.80; 364.34; 356.59 U/ml
Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Percentage of Participants With Adverse Events Including Clinically Significant Changes in Laboratory Values. — 100 percentage of participants
Periapical Periodontitis
Primary: Number of Participats Showing Efficacy (Functionality) — 18; 18 Participants
Lung Cancer
Primary: Number of Participants With 8-week Progression-Free Survival (i.e. Disease Control Rate) Stratified by Cancer Mutation Type — 11; 1; 0; 1 participants
Migraine
Primary: Visual Analog Scale — 8.1; 7.9; 7.9; 5.9 score on a scale
Dental Caries
Primary: Soft Tissue — 0 Participants
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate — 57 Participants
Cutaneous Sutures and Scar Cosmesis
Primary: Patient Posas Score — 10.2; 11.5 score on a scale
Hypertension
Primary: Change in Small Artery Elasticity — 2.4; 1.0; 0.4 (ml/mmHg × 100)
Acute Pain
Primary: Total Rescue Opioid Consumption — 166.9; 179.9; 180.2 µg/kg — p=0.736
Diabetes Mellitus, Type 2
Primary: Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment — -0.20; -0.61 Percentage change — p=0.0016
Obesity
Primary: Change in Fat Mass at 12 Weeks — -0.74; 0.42 kg
Constipation - Functional
Primary: Median Number of Observed Weekly Spontaneous Bowel Movements (SBM) Per Month — 2.66; 2.75; 2.70; 2.75 Weekly SBMs
Ameloblastoma · BRAF Gene Mutation
Primary: Tumor Response — 0; 0; 0; 0 Participants
Non-small Cell Lung Cancer (NSCLC) · Lung Metastasis
Primary: Feasibility to Perform Interstitial-Photodynamic Therapy (i-PDT) Into Tumor — 3; 0; 1; 1 Participants